Company intelligence / Profile preview

TriFlo Cardiovascular

Newport Beach, California, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

TriFlo Cardiovascular has developed the "Tricuspid Flow Optimizer," a novel implantable device designed to treat tricuspid regurgitation. The system uses a transfemoral delivery approach and features polymer leaflets that work with the native tricuspid anatomy. As of June 2025, the device remains in development and clinical evaluation; it has not yet been approved for sale or general use. A first-in-human clinical trial was scheduled to start in October 2024[2][3][7].

Therapeutic areas: Cardiovascular
Modalities: Device (implantable heart valve device)
Industry: Implantable Medical Devices

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on TriFlo Cardiovascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriFlo Cardiovascular.

Explore the full profile